Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03878524

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:39:55.992944+00:00

Published At

2024-03-04T00:00:00+00:00

Record Updated At

2024-03-04

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Anatomic Stage IV Breast Cancer AJCC v8", "Anemia", "Ann Arbor Stage III Hodgkin Lymphoma", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Castration-Resistant Prostate Carcinoma", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Hematopoietic and Lymphoid System Neoplasm", "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Breast Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Primary Myelofibrosis", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Hematologic Malignancy", "Recurrent Hodgkin Lymphoma", "Recurrent Myelodysplastic Syndrome", "Recurrent Myelodysplastic/Myeloproliferative Neoplasm", "Recurrent Myeloproliferative Neoplasm", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Hematologic Malignancy", "Refractory Hodgkin Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Myelodysplastic Syndrome", "Refractory Myelodysplastic/Myeloproliferative Neoplasm", "Refractory Non-Hodgkin Lymphoma", "Refractory Plasma Cell Myeloma", "Refractory Primary Myelofibrosis", "Refractory Small Lymphocytic Lymphoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Unresectable Pancreatic Adenocarcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2024-03-04"

protocolSection.identificationModule.nctId

"NCT03878524"

protocolSection.identificationModule.officialTitle

"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME"

protocolSection.statusModule.overallStatus

"TERMINATED"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
• Anatomic Stage IV Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Anemia (protocolSection.conditionsModule.conditions)
• Ann Arbor Stage III Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Ann Arbor Stage III Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Ann Arbor Stage IV Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Ann Arbor Stage IV Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative (protocolSection.conditionsModule.conditions)
• Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
• Castration-Resistant Prostate Carcinoma (protocolSection.conditionsModule.conditions)
• Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
• Hematopoietic and Lymphoid System Neoplasm (protocolSection.conditionsModule.conditions)
• Locally Advanced Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Breast Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
• Metastatic Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis (protocolSection.conditionsModule.conditions)
• Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (protocolSection.conditionsModule.conditions)
• Primary Myelofibrosis (protocolSection.conditionsModule.conditions)
• Recurrent Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
• Recurrent Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
• Recurrent Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
• Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
• Recurrent Hematologic Malignancy (protocolSection.conditionsModule.conditions)
• Recurrent Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
• Recurrent Myelodysplastic/Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
• Recurrent Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
• Recurrent Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Plasma Cell Myeloma (protocolSection.conditionsModule.conditions)
• Recurrent Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
• Refractory Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
• Refractory Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
• Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
• Refractory Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
• Refractory Hematologic Malignancy (protocolSection.conditionsModule.conditions)
• Refractory Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
• Refractory Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
• Refractory Myelodysplastic/Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
• Refractory Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Plasma Cell Myeloma (protocolSection.conditionsModule.conditions)
• Refractory Primary Myelofibrosis (protocolSection.conditionsModule.conditions)
• Refractory Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
• Stage II Pancreatic Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Stage III Pancreatic Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Stage IV Pancreatic Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Stage IV Prostate Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Unresectable Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.